Share this Post!

The Food and Drug Administration (FDA) warns the public from purchasing and using the following non-compliant cosmetic products imported and distributed by the Market Authorization Holder (MAH), Healthy Innovation Distribution Inc.:

1. FRESH SKINLAB 98% TOMATO GLASS SKIN WATER DROP CREAM SPF 30
2. FRESH SKINLAB 98% TOMATO GLASS SKIN SUN GEL SPF 50 PA++++
3. SUNGLOW BY FRESH TINTED LIPSCREEN SPF 50 PA++++
4. FRESH SKINLAB 98% JEJU ALOE ICE UV SUN BLOCK FOR FACE & BODY SPF 50 PA++

According to Republic Act 3720 as amended, a cosmetic shall be deemed misbranded if its labeling is false or misleading in any particular. Furthermore, the IRR of Republic Act 9711 defines “misbranding” as giving unsubstantiated claims, misinformation or misleading information on the label or other information materials.

The aforementioned cosmetic products were found non-compliant with the existing standards due to failure to substantiate the claim Sun Protection Factor (SPF) 50. Also, the MAH, Healthy Innovation Distribution Inc., has made misrepresentation and false entries in the applications for product notification based on the Centers’ post evaluation activities and product information file (PIF) audit by declaring Coreholic Co., as the manufacturer which is inconsistent from the relevant documents submitted for notification, rendering the products unauthorized.

In light of the foregoing, the public is advised not to purchase the aforementioned misbranded products. Moreover, the public is advised to always check if a cosmetic product is notified with the FDA. The FDA website (www.fda.gov.ph.) has a Search feature which may be used by typing in the name of the product before purchasing.

All concerned establishments are warned not to distribute misbranded cosmetic products.

All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that violative products are not sold or made available in the market or areas of jurisdiction.

Attachment:-> FDA-Advisory-No.2020-1757